Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?

被引：1
|
作者：
Doggrell, SA [1 ]
机构：
[1] Doggrell Biomed Commun, Auckland, New Zealand
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2004年 / 13卷 / 04期
关键词：
animal models; autosomal recessive polycystic kidney disease; nephronophthisis; OPC-31260; polycystic kidney disease; V-2; receptor antagonist;
D O I：
10.1517/eoid.13.4.431.29588
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The childhood forms of polycystic kidney disease are autosomal recessive polycystic kidney disease and nephronophthisis. In animal models of these diseases, characterised by a defect in urine concentration progressing to renal failure, the selective vasopressin receptor type 2 antagonist OPC-31260 halted the progression or even caused regression of the established disease. Vasopressin receptor type 2 antagonists should proceed to clinical trial for these polycystic kidney diseases.
引用
收藏
页码：431 / 434
页数：4
相关论文
共 50 条
12345